Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia

European Journal of Endocrinology

Volumn 169, Issue 5, 2013, Pages 705-714

  Loves, Sandra ^a   De Jong, Jos ^a   Van Sorge, Adriaan ^a   Telting, Darryl ^a   Tack, Cees J ^b   Hermus, Ad ^b   Westerterp, Klaas ^c   De Boer, Hans ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; TESTOSTERONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; BODY MASS; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ESTRADIOL BLOOD LEVEL; EXERCISE TOLERANCE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INSULIN SENSITIVITY; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MENTAL HEALTH; OBESITY; OBESITY RELATED HYPOGONADOTROPIC HYPOTESTOSTERONEMIA; PRIORITY JOURNAL; PROSTATE DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROGENS; AROMATASE INHIBITORS; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; DOUBLE-BLIND METHOD; ENERGY INTAKE; ESTRADIOL; EXERCISE TOLERANCE; HORMONES; HUMANS; HYPOGONADISM; LIPID METABOLISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NITRILES; OBESITY, MORBID; PSYCHOMETRICS; TESTOSTERONE; TRIAZOLES;

EID: 84886301206     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0190     Document Type: Article

References (41)

1. Glass AR, Swerdloff RS, Bray GA, Dahms WT & Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. Journal of Clinical Endocrinology and Metabolism 1977 45 1211-1219. (doi:10.1210/jcem-45- 6-1211)
2. Zumoff B, Strain GW, Miller KL, Rosner W, Senie R, Seres DS & Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulinbound testosterone are decreased in obese men in proportion to their degree of obesity. Journal of Clinical Endocrinology and Metabolism 1990 71 929-931. (doi:10.1210/jcem-71-4- 929)
3. Hofstra J, Loves S, vanWageningen B, Ruinemans-Koerts J, Jansen I & de Boer H. High prevalence of hypogonadotropic hypogonadismin men referred for obesity treatment. Netherlands Journal of Medicine 2008 66 103-109.
4. Giagulli VA, Kaufman JM & Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. Journal of Clinical Endocrinology and Metabolism 1994 79 997-1000. (doi:10.1210/jc.79.4.997)
5. Schneider G, Kirschner MA, Berkowitz R & Ertel NH. Increased estrogen production in obese men. Journal of Clinical Endocrinology and Metabolism 1979 48 633-638. (doi:10.1210/jcem-48-4-633)
6. Finkelstein JS, O'Dea LS, Whitcomb RW & Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropinreleasing hormone-deficient men. Journal of Clinical Endocrinology and Metabolism 1991 73 621-628. (doi:10.1210/jcem-73-3-621)
7. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A & Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism 1999 84 3673-3680. (doi:10.1210/jc.84.10.3673)
8. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L & Lavie P. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. Journal of Clinical Endocrinology and Metabolism 2002 87 3394-3398. (doi:10.1210/jc.87.7.3394)
9. Riggs BL, Khosla S & Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002 279 302.
10. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD & Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. Journal of Clinical Endocrinology and Metabolism 1998 83 1886-1892. (doi:10.1210/jc.83.6.1886)
11. Wainwright SR, Lieblich SE & Galea LA. Hypogonadism predisposes males to the development of behavioural and neuroplastic depressive phenotypes. Psychoneuroendocrinology 2011 36 1327-1341. (doi:10.1016/j.psyneuen.2011.03.004)
12. Kelleher S, Conway AJ & Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. Journal of ClinicalEndocrinology and Metabolism 2004 89 3813-3817. (doi:10.1210/jc.2004-0143)
13. Dabbs JM Jr, Hargrove MF & Heusel C. Testosterone differences among college fraternities: well-behaved vs rambunctious. Personality and Individual Differences 1996 20 157-161. (doi:10.1016/0191-8869(95)00190-5)
14. Burris AS, Banks SM, Carter CS, Davidson JM & Sherins RJ. A longterm, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. Journal of Andrology 1992 13 297-304. (doi:10.1210/er.23.3.279)
15. Loves S, Ruinemans-Koerts J & de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. European Journal of Endocrinology 2008 158 741-747. (doi:10.1530/EJE-07-0663)
16. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jc.84.10.3666)
17. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subject with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 57-63. (doi:10.2337/diacare.23.1.57)
18. Harris JA & Benedict FG. A biometric study of human basal metabolism in men. Washington, DC, USA: Carnegie Institution of Washington, 1919.
19. Westerterp KR, Wouters L & van Marken Lichtenbelt WD. The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water. Obesity Research 1995 3 (Suppl 1) 49-57.
20. Arrindell WA & Ettema JHM. Handleiding bij een mulitdimensionale psychopathologie-indicator. Klachtenlijst SCL-90. Lisse: Swets Test Servise, 1986.
21. Luteijn F, Starren J & van Dijk H. Handleiding Nederlandse Persoonlijkheidsvragenlijst. Lisse: Swets & Zeitlinger, 1985.
22. Luteijn F & Van der Ploeg FAE. Handleiding GIT. Lisse: Swets, Zeitlinger, 1983.
23. Zhou Y, Ma X,Wu C, Lu J, Zhang S, Guo J,Wu S, Ye X, Xu J & He J. Effects of anti-obesity drug on cardiovascular risk factors; a systemic review and meta-analysis of randomized controlled trials. PLoS ONE 2012 7 e39062. (doi:10.1371/journal.pone.0039062)
24. Hero M, Norjavaara E & Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2005 90 6396-6402. (doi:10.1210/jc.2005-1392)
25. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E & Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001 357 1743-1748. (doi:10.1016/S0140-6736(00)04895-9)
26. Lapauw B, T'Sjoen G, Mahmoud A, Kaufman JM & Ruige JB. Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. European Journal of Endocrinology 2008 160 397-402. (doi:10.1530/EJE-08-0881)
27. Mauras N, O'Brien K, Oerter Klein K & Hayes V. Estrogensuppression in males: metabolic effects. Journal of Clinical Endocrinology and Metabolism 2000 85 2370-2377. (doi:10.1210/jc.85.7.2370)
28. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H & Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clinical Endocrinology 2009 70 116-123. (doi:10.1111/j.1365-2265.2008.03327.x)
29. Muller M, van den Beld AW, van der Schouw YT, Grobbee DE & Lamerts SW. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. Journal of Clinical Endocrinology and Metabolism 2006 91 3988-3991. (doi:10.1210/jc.2005-2433)
30. Weissberger AJ & Ho KK. Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. Journal of Clinical Endocrinology and Metabolism 1993 76 1407-1412. (doi:10.1210/jc.76.6. 1407)
31. Rochira V, Zirilli L, Maffei L, Premrou V, Aranda C, Baldi M, Ghigo E, Aimaretti G, Carani C & Lanfranco F. Tall stature without growth hormone: four male patients with aromatase deficiency. Journal of Clinical Endocrinology and Metabolism 2010 95 1626-1633. (doi:10.1210/jc.2009-1743)
32. Vandenput L, Boonen S, van Herck E, Swinnen JV, Bouillon R & Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17-b-estradiol is a more effective bone-sparing and anabolic agent than 5-a-dihydrotestosterone. Journal of Bone and Mineral Research 2002 17 2080-2086. (doi:10.1359/jbmr.2002.17.11.2080)
33. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB & Cooke PS. Increased adipose tissue in male and female estrogen receptor-a knockout mice. PNAS 2000 97 12729-12734. (doi:10.1073/pnas.97.23.12729)
34. JonesME, ThorburnAW, Britt KL, HewittKN,WrefordNG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S et al. Aromatase-deficient (ArKO)mice have a phenotype of increased adiposity. PNAS 200097 12735-12740. (doi:10.1073/pnas.97. 23.12735)
35. Callewaert F, Venken K, Ophoff J, De Gendt JK, Torcasio A, van Lenthe GH, van Oosterwyck H, Boonen S, Bouillon R, Verhoeven G et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-a. FASEB Journal 2009 23 232-240. (doi:10.1096/fj.08-113456)
36. Belgorosky A, Guercio G, Pepe C, Saraco N & Rivarola MA. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Hormone Research 2009 72 321-330. (doi:10.1159/000249159)
37. Jones ME, Boon WC, Proietto J & Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends in Endocrinology and Metabolism 2006 17 55-64. (doi:10.1016/j.tem.2006.01.004)
38. Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O & Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. Journal of Bone and Mineral Research 2010 25 1536-1543. (doi:10.1002/jbmr.56)
39. Burnett-Bowie SA, McKay EA, Lee H & Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism 2009 94 4785-4792. (doi:10.1210/jc.2009-0739)
40. Saylam B, Efesoy O & Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones and sperm parameters in infertile men. Fertility and Sterility 2011 95 809-811. (doi:10.1016/j.fertnstert.2010.09. 021)
41. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology 2013 168 829-843. (doi:10.1530/EJE-12-0955)